Clearing zombie cells is promising in mice. What does the human evidence look like?
This LongevityTortoise guide reviews the latest peer-reviewed evidence to help you understand Quercetin & Fisetin as Senolytics and decide whether it fits into a healthy-ageing routine. We prioritise human trials, disclose limitations and never replace professional medical advice.
Senolytics — compounds that clear senescent cells — are one of the most exciting areas in longevity science, but human evidence is still early. Dasatinib + quercetin has reduced senescent-cell burden in small human trials. Fisetin shows strong effects in mice and is now entering larger human studies. Neither is proven to extend human lifespan.
Senescent cells are sometimes called "zombie cells." They stop dividing in response to stress or damage, but they do not die. Instead they secrete a cocktail of inflammatory molecules, proteases and growth factors collectively known as the senescence-associated secretory phenotype (SASP). Over time these cells accumulate in tissues and are thought to contribute to inflammation, tissue dysfunction and many age-related diseases.
The theory behind senolytics is simple: remove these cells and the tissues they occupy may function more youthfully. In animal studies, intermittent treatment with senolytic drugs can improve physical function, reduce frailty and extend healthspan — even when started in old age.
This combination was identified by Kirkland and colleagues at the Mayo Clinic. Dasatinib is a tyrosine-kinase inhibitor used as a cancer drug. Quercetin is a flavonoid found in apples, onions and tea. Together they target distinct senescent-cell survival pathways and appear more effective than either alone.
Fisetin is a flavonoid found in strawberries, apples and persimmons. Yousefzadeh et al. (2018) showed that fisetin reduced senescent-cell markers, improved tissue function and increased lifespan and healthspan in mice. Human trials are smaller and ongoing.
Quercetin has anti-inflammatory and antioxidant properties, but as a standalone senolytic it is weaker than D+Q. Many consumers take quercetin as a general polyphenol supplement rather than a true senolytic.
| Feature | Details |
|---|---|
| Feature | Dasatinib + Quercetin Dasatinib + Quercetin: Fisetin Fisetin: Quercetin alone |
| Evidence base | Small human trials Dasatinib + Quercetin: Strong animal; early human Fisetin: Weak as senolytic |
| availability | Dasatinib prescription-only; quercetin supplement Dasatinib + Quercetin: Food supplement Fisetin: Food supplement |
| Common study dose | Dasatinib + Quercetin: Intermittent pulses (e.g. 100 mg D + 1,000 mg Q for 2–3 days) Fisetin: 100–1,000 mg/day in trials Quercetin alone: 500–1,000 mg/day |
| Safety profile | Real risks; prescription supervision required Dasatinib + Quercetin: Generally well tolerated short term Fisetin: Generally well tolerated |
Senescent cells are not all bad. They help with wound healing, embryonic development and tumour suppression in some contexts. Wiping them out continuously could theoretically impair these functions. That is why almost all clinical protocols use intermittent "pulsed" schedules rather than daily use.
These sources are referenced inline throughout the article and listed below for full transparency.
"The Achilles' heel of senescent cells: from transcriptome to senolytic drugs." Identifies dasatinib + quercetin as a senolytic cocktail.
View DOI"Fisetin is a senotherapeutic that extends health and lifespan." Mouse study showing fisetin reduces senescent cells and improves healthspan and lifespan.
View DOI"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease."
View DOI"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study." Explores safety and functional outcomes of D+Q in IPF.
View DOI"Senolytic drugs: from discovery to translation." Review of the rationale, preclinical evidence and early clinical data for senolytic interventions.
View DOIA senolytic is a compound that selectively clears senescent cells — aged cells that have stopped dividing but remain metabolically active and release inflammatory signals. Removing them is one strategy being studied to improve healthspan.
Early-phase human trials suggest that combinations such as dasatinib + quercetin can reduce senescent-cell burden in some tissues. Fisetin is promising in animal models and is now being tested in humans, but definitive human data are still limited.
The most studied protocol uses dasatinib (a cancer drug) plus quercetin (a plant flavonoid), taken intermittently in pulses. It is being investigated in clinical trials but is not approved for anti-ageing and should not be used without specialist supervision.
Short-term intermittent use in trials has been relatively well tolerated, but long-term safety is unknown. Risks include infection, impaired wound healing and off-target effects. Dasatinib is a prescription cancer drug with serious side effects.
The content on this site is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any supplement, especially if you are pregnant, nursing, taking medication or have a medical condition. Do not use prescription drugs such as dasatinib outside specialist care.